EA Pharma Co., Ltd.: Clinical Trials

15 trials sponsored by EA Pharma Co., Ltd., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 1 terminated, 1 withdrawn. 7 Phase 1, 6 Phase 2, 3 Phase 3, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 17Completed 6, Withdrawn 1
Phase 26Completed 5, Terminated 1
Phase 33Completed 3
Early Phase 11Completed 1

Follow EA Pharma Co., Ltd.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease
Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g), Elobixibat 10mg + cholestyramine powder placebo, Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g) - Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Phase 2CompletedYokohama City University1022020-01-292021-11-16
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants
EA1080, EA1080-matching placebo - Healthy Volunteers
Phase 1CompletedEA Pharma Co., Ltd.1842020-01-092023-12-26
A Study of E6011 in Participants With Active Crohn's Disease
E6011, Placebo - Crohn's Disease
Phase 2CompletedEA Pharma Co., Ltd.252019-04-252025-04-02
A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants
E3112, Placebo - Healthy Male Participants
Phase 1CompletedEA Pharma Co., Ltd.242019-04-222021-03-15
A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis
AJM300, Placebo - Colitis, Ulcerative
Phase 3CompletedEA Pharma Co., Ltd.1982018-06-062023-07-21
A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Participants
[14C]-E6007 - Healthy Male Participants
Phase 1CompletedEA Pharma Co., Ltd.62018-04-172018-08-29
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Male Participants
E6130, Placebo - Healthy Participants
Phase 1WithdrawnEA Pharma Co., Ltd.2017-12-212018-07-31
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State
AJM347, Placebo - Healthy Participants
Phase 1CompletedEA Pharma Co., Ltd.2002017-07-252018-08-29
Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid
E6011, Placebo - Primary Biliary Cholangitis
Phase 2TerminatedEA Pharma Co., Ltd.292017-05-292019-01-04
A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects
Placebo, E3112 - Healthy Male Volunteers
Early Phase 1CompletedEA Pharma Co., Ltd.292017-01-252018-11-14
Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis
E6007, Placebo - Moderate Active Ulcerative Colitis
Phase 2CompletedEA Pharma Co., Ltd.1472016-11-282019-10-04
General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation
AJG555 - Chronic Constipation
Phase 3CompletedEA Pharma Co., Ltd.392016-11-152017-10-24
A Single Dose Study of E6130 in Japanese Healthy Adult Male Subjects
E6130, Placebo - Japanese Healthy Adult Male Participants
Phase 1CompletedEA Pharma Co., Ltd.562016-09-262018-09-06
A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease
E6011 2 mg/kg, E6011 5 mg/kg, E6011 10 mg/kg - Crohn's Disease
Phase 1 / Phase 2CompletedEA Pharma Co., Ltd.282014-04-052023-01-30
A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets
NE-58095 IR, NE-58095 IR Placebo, NE-58095 DR - Involutional Osteoporosis
Phase 2 / Phase 3CompletedTakeda8712014-02-012017-02-23

Conditions studied

Crohn Disease (2)  ·  Colitis (1)  ·  Colitis, Ulcerative (1)  ·  Constipation (1)  ·  Gastroenteritis (1)  ·  Inflammatory Bowel Diseases (1)  ·  Liver Cirrhosis, Biliary (1)  ·  Non-alcoholic Fatty Liver Disease (1)  ·  Osteoporosis (1)

Interventions

quetmolimab (3)  ·  AJM300 (1)  ·  Cholestyramine Resin (1)  ·  elobixibat (1)

Countries

Japan (11)  ·  United Kingdom (3)  ·  Czechia (1)  ·  Hungary (1)  ·  Poland (1)  ·  Russia (1)

Top investigators

Takaomi Kessoku, MD.,PhD. (1)

Results publications

PMID 29805116, PMID 32907904, PMID 33599356, PMID 35366419

NIH funding

2017 (2), 2018 (1), 2019 (1)